IRIDEX Corporation Logo

IRIDEX Corporation

IRIX

(1.0)
Stock Price

1,94 USD

-24.05% ROA

-52.93% ROE

-6.28x PER

Market Cap.

48.745.025,00 USD

24.01% DER

0% Yield

-14.21% NPM

IRIDEX Corporation Stock Analysis

IRIDEX Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

IRIDEX Corporation Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (9%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (2.36x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

4 ROE

Negative ROE (-48.09%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-22.75%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-15) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

IRIDEX Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

IRIDEX Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

IRIDEX Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

IRIDEX Corporation Revenue
Year Revenue Growth
1995 8.800.000
1996 12.400.000 29.03%
1997 18.100.000 31.49%
1998 23.600.000 23.31%
1999 26.762.000 11.82%
2000 33.437.000 19.96%
2001 27.275.000 -22.59%
2002 30.634.000 10.96%
2003 31.699.000 3.36%
2004 32.810.000 3.39%
2005 37.029.000 11.39%
2006 35.904.000 -3.13%
2007 55.532.000 35.35%
2008 48.528.000 -14.43%
2009 43.212.000 -12.3%
2010 43.694.000 1.1%
2011 33.159.000 -31.77%
2012 33.859.000 2.07%
2013 38.273.000 11.53%
2014 42.814.000 10.61%
2015 41.757.000 -2.53%
2016 46.158.000 9.53%
2017 41.593.000 -10.98%
2018 42.600.000 2.36%
2019 43.447.000 1.95%
2020 36.347.000 -19.53%
2021 53.903.000 32.57%
2022 56.972.000 5.39%
2023 51.400.000 -10.84%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

IRIDEX Corporation Research and Development Expenses
Year Research and Development Expenses Growth
1995 0
1996 1.300.000 100%
1997 1.700.000 23.53%
1998 3.100.000 45.16%
1999 3.925.000 21.02%
2000 5.265.000 25.45%
2001 4.808.000 -9.5%
2002 4.315.000 -11.43%
2003 4.032.000 -7.02%
2004 4.509.000 10.58%
2005 4.195.000 -7.49%
2006 5.511.000 23.88%
2007 5.779.000 4.64%
2008 4.009.000 -44.15%
2009 3.609.000 -11.08%
2010 3.814.000 5.37%
2011 3.913.000 2.53%
2012 4.385.000 10.76%
2013 3.684.000 -19.03%
2014 4.629.000 20.41%
2015 5.214.000 11.22%
2016 5.365.000 2.81%
2017 5.730.000 6.37%
2018 4.006.000 -43.04%
2019 3.682.000 -8.8%
2020 3.282.000 -12.19%
2021 6.868.000 52.21%
2022 7.175.000 4.28%
2023 6.164.000 -16.4%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

IRIDEX Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 4.873.000 100%
2010 4.488.000 -8.58%
2011 4.259.000 -5.38%
2012 4.926.000 13.54%
2013 5.023.000 1.93%
2014 6.034.000 16.76%
2015 5.550.000 -8.72%
2016 7.638.000 27.34%
2017 8.260.000 7.53%
2018 9.551.000 13.52%
2019 8.379.000 -13.99%
2020 6.620.000 -26.57%
2021 8.859.000 25.27%
2022 7.557.000 -17.23%
2023 7.780.000 2.87%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

IRIDEX Corporation EBITDA
Year EBITDA Growth
1995 1.400.000
1996 500.000 -180%
1997 2.500.000 80%
1998 2.000.000 -25%
1999 2.555.000 21.72%
2000 3.663.000 30.25%
2001 -1.178.000 410.95%
2002 717.000 264.3%
2003 602.000 -19.1%
2004 -762.000 179%
2005 2.244.000 133.96%
2006 -4.223.000 153.14%
2007 -8.107.000 47.91%
2008 1.049.000 872.83%
2009 2.518.000 58.34%
2010 3.312.000 23.97%
2011 2.344.000 -41.3%
2012 -1.660.000 241.2%
2013 2.633.000 163.05%
2014 2.587.000 -1.78%
2015 288.000 -798.26%
2016 -2.325.000 112.39%
2017 -13.168.000 82.34%
2018 -12.868.000 -2.33%
2019 -8.974.000 -43.39%
2020 -6.583.000 -36.32%
2021 -7.533.000 12.61%
2022 -7.542.000 0.12%
2023 -6.752.000 -11.7%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

IRIDEX Corporation Gross Profit
Year Gross Profit Growth
1995 6.100.000
1996 7.700.000 20.78%
1997 10.900.000 29.36%
1998 14.000.000 22.14%
1999 15.791.000 11.34%
2000 19.692.000 19.81%
2001 13.070.000 -50.67%
2002 13.588.000 3.81%
2003 14.071.000 3.43%
2004 14.888.000 5.49%
2005 18.175.000 18.09%
2006 18.805.000 3.35%
2007 24.284.000 22.56%
2008 19.679.000 -23.4%
2009 20.273.000 2.93%
2010 20.903.000 3.01%
2011 16.290.000 -28.32%
2012 16.346.000 0.34%
2013 18.587.000 12.06%
2014 21.405.000 13.17%
2015 19.953.000 -7.28%
2016 20.839.000 4.25%
2017 15.503.000 -34.42%
2018 17.471.000 11.26%
2019 17.939.000 2.61%
2020 15.558.000 -15.3%
2021 22.831.000 31.86%
2022 25.368.000 10%
2023 22.484.000 -12.83%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

IRIDEX Corporation Net Profit
Year Net Profit Growth
1995 1.000.000
1996 1.000.000 0%
1997 2.100.000 52.38%
1998 1.700.000 -23.53%
1999 1.618.000 -5.07%
2000 2.416.000 33.03%
2001 -1.273.000 289.79%
2002 150.000 948.67%
2003 371.000 59.57%
2004 -402.000 192.29%
2005 1.671.000 124.06%
2006 -5.753.000 129.05%
2007 -22.272.000 74.17%
2008 -7.370.000 -202.2%
2009 2.585.000 385.11%
2010 3.046.000 15.13%
2011 2.610.000 -16.7%
2012 1.438.000 -81.5%
2013 2.231.000 35.54%
2014 10.038.000 77.77%
2015 474.000 -2017.72%
2016 -11.713.000 104.05%
2017 -12.867.000 8.97%
2018 -12.813.000 -0.42%
2019 -8.813.000 -45.39%
2020 -6.329.000 -39.25%
2021 -5.225.000 -21.13%
2022 -7.547.000 30.77%
2023 -7.016.000 -7.57%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

IRIDEX Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1995 1
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 -1 0%
2007 -3 100%
2008 -1 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 1 100%
2015 0 0%
2016 -1 100%
2017 -1 0%
2018 -1 0%
2019 -1 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

IRIDEX Corporation Free Cashflow
Year Free Cashflow Growth
1995 700.000
1996 -1.900.000 136.84%
1997 -1.900.000 0%
1998 -2.800.000 32.14%
1999 2.271.000 223.29%
2000 -726.000 412.81%
2001 -4.126.000 82.4%
2002 2.235.000 284.61%
2003 4.500.000 50.33%
2004 385.000 -1068.83%
2005 2.430.000 84.16%
2006 -1.900.000 227.89%
2007 -1.469.000 -29.34%
2008 -96.000 -1430.21%
2009 6.566.000 101.46%
2010 3.286.000 -99.82%
2011 2.845.000 -15.5%
2012 -837.000 439.9%
2013 387.000 316.28%
2014 3.446.000 88.77%
2015 -1.468.000 334.74%
2016 -1.206.000 -21.72%
2017 -4.140.000 70.87%
2018 -10.465.000 60.44%
2019 -8.041.000 -30.15%
2020 -3.334.000 -141.18%
2021 8.004.000 141.65%
2022 -9.805.000 181.63%
2023 -500 -1960900%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

IRIDEX Corporation Operating Cashflow
Year Operating Cashflow Growth
1995 900.000
1996 -1.300.000 169.23%
1997 -100.000 -1200%
1998 -2.000.000 95%
1999 2.862.000 169.88%
2000 -74.000 3967.57%
2001 -3.635.000 97.96%
2002 2.519.000 244.3%
2003 5.103.000 50.64%
2004 771.000 -561.87%
2005 2.770.000 72.17%
2006 -1.385.000 300%
2007 -522.000 -165.33%
2008 -96.000 -443.75%
2009 6.798.000 101.41%
2010 3.479.000 -95.4%
2011 3.048.000 -14.14%
2012 -443.000 788.04%
2013 767.000 157.76%
2014 4.014.000 80.89%
2015 -593.000 776.9%
2016 -144.000 -311.81%
2017 -3.565.000 95.96%
2018 -10.025.000 64.44%
2019 -7.913.000 -26.69%
2020 -3.237.000 -144.45%
2021 8.217.000 139.39%
2022 -9.519.000 186.32%
2023 -500 -1903700%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

IRIDEX Corporation Capital Expenditure
Year Capital Expenditure Growth
1995 200.000
1996 600.000 66.67%
1997 1.800.000 66.67%
1998 800.000 -125%
1999 591.000 -35.36%
2000 652.000 9.36%
2001 491.000 -32.79%
2002 284.000 -72.89%
2003 603.000 52.9%
2004 386.000 -56.22%
2005 340.000 -13.53%
2006 515.000 33.98%
2007 947.000 45.62%
2008 0 0%
2009 232.000 100%
2010 193.000 -20.21%
2011 203.000 4.93%
2012 394.000 48.48%
2013 380.000 -3.68%
2014 568.000 33.1%
2015 875.000 35.09%
2016 1.062.000 17.61%
2017 575.000 -84.7%
2018 440.000 -30.68%
2019 128.000 -243.75%
2020 97.000 -31.96%
2021 213.000 54.46%
2022 286.000 25.52%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

IRIDEX Corporation Equity
Year Equity Growth
1995 4.700.000
1996 21.500.000 78.14%
1997 23.900.000 10.04%
1998 25.900.000 7.72%
1999 27.504.000 5.83%
2000 30.500.000 9.82%
2001 29.833.000 -2.24%
2002 30.198.000 1.21%
2003 30.834.000 2.06%
2004 31.783.000 2.99%
2005 34.517.000 7.92%
2006 32.157.000 -7.34%
2007 18.810.000 -70.96%
2008 11.746.000 -60.14%
2009 15.026.000 21.83%
2010 19.427.000 22.65%
2011 22.426.000 13.37%
2012 21.905.000 -2.38%
2013 25.854.000 15.27%
2014 33.736.000 23.36%
2015 33.688.000 -0.14%
2016 39.160.000 13.97%
2017 30.522.000 -28.3%
2018 29.961.000 -1.87%
2019 22.705.000 -31.96%
2020 17.366.000 -30.74%
2021 23.299.000 25.46%
2022 17.231.000 -35.22%
2023 12.064.000 -42.83%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

IRIDEX Corporation Assets
Year Assets Growth
1995 6.400.000
1996 23.700.000 73%
1997 26.700.000 11.24%
1998 28.400.000 5.99%
1999 32.665.000 13.06%
2000 35.025.000 6.74%
2001 33.788.000 -3.66%
2002 34.272.000 1.41%
2003 35.839.000 4.37%
2004 39.093.000 8.32%
2005 41.104.000 4.89%
2006 40.177.000 -2.31%
2007 46.654.000 13.88%
2008 28.225.000 -65.29%
2009 28.291.000 0.23%
2010 29.220.000 3.18%
2011 32.149.000 9.11%
2012 28.912.000 -11.2%
2013 33.677.000 14.15%
2014 41.818.000 19.47%
2015 41.823.000 0.01%
2016 48.144.000 13.13%
2017 41.646.000 -15.6%
2018 41.672.000 0.06%
2019 34.813.000 -19.7%
2020 27.969.000 -24.47%
2021 48.687.000 42.55%
2022 42.290.000 -15.13%
2023 34.949.000 -21%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

IRIDEX Corporation Liabilities
Year Liabilities Growth
1995 1.700.000
1996 2.200.000 22.73%
1997 2.800.000 21.43%
1998 2.500.000 -12%
1999 5.161.000 51.56%
2000 4.525.000 -14.06%
2001 3.955.000 -14.41%
2002 4.074.000 2.92%
2003 5.005.000 18.6%
2004 7.310.000 31.53%
2005 6.587.000 -10.98%
2006 8.020.000 17.87%
2007 27.844.000 71.2%
2008 16.479.000 -68.97%
2009 13.265.000 -24.23%
2010 9.793.000 -35.45%
2011 9.723.000 -0.72%
2012 7.007.000 -38.76%
2013 7.823.000 10.43%
2014 8.082.000 3.2%
2015 8.135.000 0.65%
2016 8.984.000 9.45%
2017 11.124.000 19.24%
2018 11.711.000 5.01%
2019 12.108.000 3.28%
2020 10.603.000 -14.19%
2021 25.388.000 58.24%
2022 25.059.000 -1.31%
2023 22.885.000 -9.5%

IRIDEX Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.36
Net Income per Share
-0.48
Price to Earning Ratio
-6.28x
Price To Sales Ratio
0.89x
POCF Ratio
-8.74
PFCF Ratio
-8.53
Price to Book Ratio
4.04
EV to Sales
0.76
EV Over EBITDA
-5.25
EV to Operating CashFlow
-7.49
EV to FreeCashFlow
-7.3
Earnings Yield
-0.16
FreeCashFlow Yield
-0.12
Market Cap
0,05 Bil.
Enterprise Value
0,04 Bil.
Graham Number
2.83
Graham NetNet
-0.23

Income Statement Metrics

Net Income per Share
-0.48
Income Quality
0.93
ROE
-0.53
Return On Assets
-0.22
Return On Capital Employed
-0.34
Net Income per EBT
1.01
EBT Per Ebit
0.93
Ebit per Revenue
-0.15
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0.15
Research & Developement to Revenue
0.12
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.43
Operating Profit Margin
-0.15
Pretax Profit Margin
-0.14
Net Profit Margin
-0.14

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.34
Free CashFlow per Share
-0.35
Capex to Operating CashFlow
0.03
Capex to Revenue
-0
Capex to Depreciation
-0.07
Return on Invested Capital
-0.53
Return on Tangible Assets
-0.24
Days Sales Outstanding
54.24
Days Payables Outstanding
30.75
Days of Inventory on Hand
119.05
Receivables Turnover
6.73
Payables Turnover
11.87
Inventory Turnover
3.07
Capex per Share
-0.01

Balance Sheet

Cash per Share
0,49
Book Value per Share
0,74
Tangible Book Value per Share
0.58
Shareholders Equity per Share
0.74
Interest Debt per Share
0.08
Debt to Equity
0.24
Debt to Assets
0.08
Net Debt to EBITDA
0.88
Current Ratio
2.64
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.24
Working Capital
0,02 Bil.
Intangibles to Total Assets
0.08
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
10623500
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

IRIDEX Corporation Dividends
Year Dividends Growth

IRIDEX Corporation Profile

About IRIDEX Corporation

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

CEO
Mr. David I. Bruce
Employee
130
Address
1212 Terra Bella Avenue
Mountain View, 94043

IRIDEX Corporation Executives & BODs

IRIDEX Corporation Executives & BODs
# Name Age
1 Mr. David I. Bruce
President, Chief Executive Officer & Director
70
2 Mr. Fuad Ahmad
Interim Chief Financial Officer
70
3 Mr. Patrick Mercer
Chief Operating Officer
70
4 Ms. Leigh Salvo
Head of Investor Relations
70

IRIDEX Corporation Competitors